E.S. Gershtein

2026

1. Soluble forms of the PD-1 receptor and its ligand PD-L1 in the blood serum of breast cancer patients and their relationship with clinical and morphological features of the disease Technologies of Living Systems, No. 1, 2026 pp. 31-38

2025

1. Clinical and laboratory significance of GFAP and S100 content in blood serum of patients with various brain pathologies Technologies of Living Systems, No. 4, 2025 pp. 22-31
2. IGF-I content in blood serum and tumor tissue of ovarian cancer patients Technologies of Living Systems, No. 3, 2025 pp. 34-43
3. Soluble forms of E-cadherin, N-cadherin and VE-cadherin in patients with ovarian cancer Technologies of Living Systems, No. 1, 2025 pp. 22-30

2022

1. Content of the soluble form of programmed cell death receptor protein sPD-1 and its ligand sPD-L1 in blood serum of colorectal cancer patients Technologies of Living Systems, No. 2, 2022 pp. 5-13

2021

1. Key immune checkpoints and their inhibitors in the therapy of bone tumors. Part 2. Additional targets for immunotherapy of bone tumors and markers of its efficiency Technologies of Living Systems, No. 1, 2021 pp. 18-31
2. Key immune checkpoints and their inhibitors in the therapy of bone tumors. Part 1. Signaling system of programmed cell death protein 1 - PD-1/PD-L Technologies of Living Systems, No. 1, 2021 pp. 5-17

2020

1. Survival of Ewing sarcoma and chondrosarcoma patients in relation to matrix metalloproteinases and their tissue inhibitors levels in blood serum Achievements of Modern Radioelectronics, No. 1, 2020 pp. 15-22
2. Clinical implication of the programmed cell death-1 protein PD-1 and its ligand PD-L1 in ovarian cancer (review) Technologies of Living Systems, No. 3, 2020 pp. 5-15

2019

1. Marker KIM-1 in early diagnostics of renal-cell cancer Technologies of Living Systems, No. 1, 2019 pp. 5-20

2018

1. METABOLISM OF HOMOCYSTEIN AND CYSTEIN ROLE IN BREAST CANCER Technologies of Living Systems, No. 1, 2018 pp. 29-40

2015

1. Insulin-like growth factors and serum igf binding proteins in ovarian tumor patients Вопросы биологической, медицинской и фармацевтической химии, No. 6, 2015 pp. 49-53
2. Morphological features of tumors and the matrix metalloproteinases in the blood plasma of patients with gastric cancer Вопросы биологической, медицинской и фармацевтической химии, No. 6, 2015 pp. 42-48

2014

1. Vegf signaling pathway components and matrix metalloproteinases - in tumors of patients with ovarian neoplasms Вопросы биологической, медицинской и фармацевтической химии, No. 8, 2014 pp. 47-52
2. Tumor molecular markers in clinical oncology Technologies of Living Systems, No. 2, 2014 pp. 3-18

2013

1. Inculin-like growth factors in breast cancer patients - serum Вопросы биологической, медицинской и фармацевтической химии, No. 9, 2013 pp. 68-71
2. Inculin-like growth factors in colorectal cancer patients - serum Вопросы биологической, медицинской и фармацевтической химии, No. 8, 2013 pp. 69-75
3. System of insulin-like growth factors in patients with cin and invasive cervical cancer Technologies of Living Systems, No. 4, 2013 pp. 47-52
4. Evaluation of tumor necrosis factor α and interleukin 6 content in parotid salivary fluid of ductal chronic sialadenitis patients Вопросы биологической, медицинской и фармацевтической химии, No. 4, 2013 pp. 50-56
5. Comparative elisa study of metalloproteinases 2, 7, 9 and their type 2 tissue inhibitor in the tumors and plasma of gastric cancer Technologies of Living Systems, No. 3, 2013 pp. 48-52
6. Clinical prospects of the key NF-B system components study in the tumors of breast cancer patients Technologies of Living Systems, No. 2, 2013 pp. 66-72
7. Epidermal growth factor receptors and their ligancds in malignant tumours: significance and prospects in clinic Technologies of Living Systems, No. 2, 2013 pp. 50-65
8. Vascular endothelial growth factor as a key angiogenesis regulator and clinically valuable marker in different malignant neoplasms Technologies of Living Systems, No. 2, 2013 pp. 18-33

2012

1. Matrix Metalloproteinases and Inflammatory Cytokines Content in oral Fluid of Patients with Different Constructive Materials of Teeth and Denture Restorations Вопросы биологической, медицинской и фармацевтической химии, No. 10, 2012 pp. 47-51
2. Clinical Prospects of Matrix Metalloproteinases 2, 7, 9 and Their Tissue Inhibitors Study in Colorectal Cancer Patients Вопросы биологической, медицинской и фармацевтической химии, No. 10, 2012 pp. 41-46
3. Vascular Endothelial Growth Factor and its Type 1 and 2 Receptors in Ovarian Tumor Patients - Serum Вопросы биологической, медицинской и фармацевтической химии, No. 10, 2012 pp. 30-35
4. Serum Insulin-Like Growth Factors 1 and 2 and Insulin-Like Growth Factors Binding Proteins 1 and 3 in CIN and Invasive Cervical Cancer as Perspective Markers of Disease Progression Вопросы биологической, медицинской и фармацевтической химии, No. 10, 2012 pp. 21-25
5. Inculin-like Growth Factors in Breast Cancer Patients - Serum Вопросы биологической, медицинской и фармацевтической химии, No. 10, 2012 pp. 16-20
6. Prognostic significance of urokinase and tissue type plasminogen activators and their type 1 inhibitor in the tumors of colorectal cancer oatients: results of 10 years follow-up Technologies of Living Systems, No. 3, 2012 pp. 42-49

2011

1. Clinical Prospects of the Study of NF-κB Signaling Pathway Components Expression and Activity iN tHE Tumors of Breast Cancer Patients Technologies of Living Systems, No. 8, 2011 pp. 14-23
2. Matrix Metalloproteinases in Ovarian Cancer Patients Technologies of Living Systems, No. 7, 2011 pp. 50-58матриксная мета
3. IGF and their Receptors in Breast Cancer Technologies of Living Systems, No. 7, 2011 pp. 3-11
4. Clinical Prospects of Matrix Metalloproteinases and Their Tissue Inhibitors Study in Ovarian Cancer Patients Вопросы биологической, медицинской и фармацевтической химии, No. 10, 2011 pp. 27-36
5. Comparative immunoenzymatic study of nuclear transcription factor NF-κB, its inhibitor IκBα, and upstream effector protein kinase Akt1 expression and activity in the tumors of breast cancer patients Вопросы биологической, медицинской и фармацевтической химии, No. 8, 2011 pp. 56-61